MCID: BRS099
MIFTS: 61

Breast Ductal Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Breast Ductal Carcinoma

MalaCards integrated aliases for Breast Ductal Carcinoma:

Name: Breast Ductal Carcinoma 12 15
Ductal Breast Carcinoma 54 6 70
Mammary Ductal Carcinoma 70
Carcinoma, Ductal 44
Ductal Carcinoma 70
Duct Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3007
MeSH 44 D044584
SNOMED-CT 67 82711006
UMLS 70 C0021367 C1176475 C1527349

Summaries for Breast Ductal Carcinoma

Disease Ontology : 12 A breast carcinoma that derives from the lining of milk ducts.

MalaCards based summary : Breast Ductal Carcinoma, also known as ductal breast carcinoma, is related to bile duct cancer and breast cystic hypersecretory carcinoma. An important gene associated with Breast Ductal Carcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are ERK Signaling and Nanog in Mammalian ESC Pluripotency. The drugs Sufentanil and Ondansetron have been mentioned in the context of this disorder. Affiliated tissues include breast, lymph node and pancreas, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading

Related Diseases for Breast Ductal Carcinoma

Diseases related to Breast Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 522)
# Related Disease Score Top Affiliating Genes
1 bile duct cancer 32.8 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
2 breast cystic hypersecretory carcinoma 32.4 ERBB2 CDH1
3 intrahepatic cholangiocarcinoma 32.3 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
4 bile duct adenocarcinoma 32.1 TP53 ERBB2 EGFR CTNNB1 CDH1
5 cholangiocarcinoma 32.1 TP53 TFF1 KRT8 ERBB2 EGFR CTNNB1
6 pleomorphic adenoma 31.4 TP53 ERBB2 CTNNB1
7 in situ carcinoma 31.4 TP53 PIP PGR KRT8 ESR1 ERBB2
8 adenoma 31.3 TP53 MKI67 CTNNB1 CDH1 CCND1
9 ductal carcinoma in situ 31.3 TP53 PIP PGR MKI67 KRT8 ESR1
10 salivary gland carcinoma 31.1 TP53 ERBB2 EGFR BRCA1
11 cystadenocarcinoma 31.0 TP53 PGR ERBB2 BRCA1
12 tubular adenocarcinoma 30.9 PGR ESR1 ERBB2 EGFR CTNNB1 CDH1
13 adenocarcinoma 30.9 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
14 transitional cell carcinoma 30.9 TP53 NME1 MKI67 KRT8 ERBB2 EGFR
15 renal cell carcinoma, papillary, 1 30.8 TP53 ERBB2 EGFR CTNNB1
16 comedo carcinoma 30.8 TP53 PGR ESR1 ERBB2
17 cholecystitis 30.8 TP53 EGFR CDH1
18 breast cancer 30.8 ZFAS1 VEGFD TP53 TFF1 RAD54L PIP
19 papillary adenocarcinoma 30.8 TP53 PIP PGR NME1 ERBB2 CDH1
20 gallbladder cancer 30.8 TP53 ERBB2 EGFR CTNNB1 CDH1
21 sporadic breast cancer 30.7 TP53 PGR ESR1 ERBB2 EGFR CCND1
22 mucoepidermoid carcinoma 30.7 TP53 MKI67 ERBB2 EGFR CTNNB1 CDH3
23 breast adenoid cystic carcinoma 30.6 PGR ESR1 ERBB2
24 papillary carcinoma 30.6 PGR NME1 ESR1 ERBB2 CDH1
25 pancreatic ductal carcinoma 30.6 TP53 ERBB2 EGFR CDH1
26 eyelid carcinoma 30.6 TFF1 PIP
27 polymorphous low-grade adenocarcinoma 30.6 MKI67 CTNNB1 CCND1
28 keratinizing squamous cell carcinoma 30.5 TP53 EGFR CDH1
29 carcinosarcoma 30.5 TP53 PGR ERBB2 EGFR CTNNB1 CDH1
30 linitis plastica 30.5 PIP PGR ERBB2 CDH1
31 mucinous adenocarcinoma 30.5 TP53 PGR ESR1 ERBB2 EGFR
32 mammary analogue secretory carcinoma 30.5 TP53 EGFR CTNNB1 CCND1
33 adenosquamous carcinoma 30.5 TP53 KRT8 EGFR CTSD
34 female breast cancer 30.5 TP53 PGR ESR1 ERBB2 BRCA1
35 clear cell renal cell carcinoma 30.4 TP53 EGFR CTNNB1 CDH1 CCND1
36 apocrine adenocarcinoma 30.4 PIP PGR ESR1 ERBB2 EGFR
37 papilloma 30.3 TP53 KRT8 ERBB2 EGFR CCND1
38 intravenous leiomyomatosis 30.3 PGR ESR1
39 pancreatic ductal adenocarcinoma 30.3 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
40 vaginal cancer 30.3 TP53 PGR ESR1
41 mammary paget's disease 30.3 PIP PGR KRT8 ESR1 ERBB2 EGFR
42 nasopharyngeal carcinoma 30.3 TP53 NME1 EGFR CTNNB1 CDH1 CCND1
43 estrogen-receptor positive breast cancer 30.3 TP53 PGR ESR1 ERBB2 EGFR CCND1
44 squamous cell carcinoma 30.3 TP53 NME1 MKI67 ERBB2 EGFR CTNNB1
45 oral cancer 30.2 TP53 EGFR CDH1 CCND1
46 bladder urothelial carcinoma 30.2 TP53 ERBB2 CTNNB1 CDH1 CCND1
47 angiomyolipoma 30.2 VEGFD PGR ESR1
48 prostatic hypertrophy 30.2 PGR ESR1 EGFR
49 lymphoepithelioma-like carcinoma 30.2 KRT8 EGFR CDH1
50 breast adenocarcinoma 30.2 TP53 PIP PGR ESR1 ERBB2 EGFR

Graphical network of the top 20 diseases related to Breast Ductal Carcinoma:



Diseases related to Breast Ductal Carcinoma

Symptoms & Phenotypes for Breast Ductal Carcinoma

GenomeRNAi Phenotypes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.35 CCND1 ESR1 MKI67 PIP VEGFD
2 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.32 CTNNB1

MGI Mouse Phenotypes related to Breast Ductal Carcinoma:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.34 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
2 cellular MP:0005384 10.33 BRCA1 CCND1 CDH1 CTNNB1 CTSD EGFR
3 endocrine/exocrine gland MP:0005379 10.32 BRCA1 CCND1 CDH1 CDH3 CTNNB1 CTSD
4 digestive/alimentary MP:0005381 10.31 BRCA1 CCND1 CDH1 CTNNB1 CTSD EGFR
5 growth/size/body region MP:0005378 10.31 BRCA1 CCND1 CDH1 CTNNB1 CTSD EGFR
6 homeostasis/metabolism MP:0005376 10.3 BRCA1 CCND1 CDH1 CTNNB1 CTSD EGFR
7 hematopoietic system MP:0005397 10.26 BRCA1 CCND1 CTNNB1 CTSD EGFR ESR1
8 immune system MP:0005387 10.25 BRCA1 CCND1 CDH1 CTNNB1 CTSD EGFR
9 embryo MP:0005380 10.18 BRCA1 CDH1 CTNNB1 EGFR ERBB2 ESR1
10 integument MP:0010771 10.18 BRCA1 CCND1 CDH1 CDH3 CTNNB1 CTSD
11 mortality/aging MP:0010768 10.17 BRCA1 CCND1 CDH1 CTNNB1 CTSD EGFR
12 neoplasm MP:0002006 10.03 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
13 limbs/digits/tail MP:0005371 9.91 BRCA1 CTNNB1 EGFR ERBB2 ESR1 PGR
14 normal MP:0002873 9.73 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2
15 no phenotypic analysis MP:0003012 9.7 CDH1 CTNNB1 EGFR ESR1 MKI67 PGR
16 reproductive system MP:0005389 9.36 BRCA1 CCND1 CDH1 CTNNB1 EGFR ERBB2

Drugs & Therapeutics for Breast Ductal Carcinoma

Drugs for Breast Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
2
Ondansetron Approved Phase 4 99614-02-5 4595
3
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
4 Analgesics Phase 4
5 Anesthetics Phase 4
6 Anesthetics, Local Phase 4
7 Narcotics Phase 4
8 Anesthetics, General Phase 4
9 Analgesics, Opioid Phase 4
10 Anesthetics, Intravenous Phase 4
11
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
12
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
13
Toremifene Approved, Investigational Phase 3 89778-26-7 3005573
14
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1 9903
15
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
16
Lapatinib Approved, Investigational Phase 2, Phase 3 231277-92-2, 388082-78-8 208908 9941095
17
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
18
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
19
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
20
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
21
Metformin Approved Phase 3 657-24-9 4091 14219
22
Tamoxifen Approved Phase 3 10540-29-1 2733526
23
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
24
Sodium citrate Approved, Investigational Phase 3 68-04-2
25
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
26
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
27
Exemestane Approved, Investigational Phase 3 107868-30-4 60198
28
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
29
Fluorouracil Approved Phase 3 51-21-8 3385
30
Epirubicin Approved Phase 3 56420-45-2 41867
31
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
32
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
33
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
34
Goserelin Approved Phase 2, Phase 3 65807-02-5 47725 5311128
35
Leuprolide Approved, Investigational Phase 2, Phase 3 53714-56-0 3911 657181
36
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
37
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
38
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
39
Atamestane Investigational Phase 3 96301-34-7
40
Medroxyprogesterone Phase 3 520-85-4 10631
41 Contraceptive Agents, Male Phase 3
42 Anti-Infective Agents Phase 3
43
Liposomal doxorubicin Phase 3 31703
44 Parasympatholytics Phase 3
45 Muscarinic Antagonists Phase 3
46 Neurotransmitter Agents Phase 3
47 Cholinergic Agents Phase 3
48 Mandelic Acids Phase 3
49 Cholinergic Antagonists Phase 3
50 Immunologic Factors Phase 3

Interventional clinical trials:

(show top 50) (show all 238)
# Name Status NCT ID Phase Drugs
1 A Clinical Evaluation Of Adipose Derived Regenerative Cells In The Treatment Of Patients With BrEast Deformities Post Segmental Breast ResecTion (Lumpectomy) With Or Without Radiation ThErapy. A Phase IV Post Market Study. Completed NCT00616135 Phase 4
2 Electronic Xoft Intersociety Brachytherapy Trial Completed NCT00742222 Phase 4
3 The Ultrasound-guided Multiple-injection Costotransverse Block for Mastectomy and Primary Reconstructive Surgery. A Double Blind, Randomised, Placebo Controlled Trial. Recruiting NCT04248179 Phase 4 Ropivacaine injection;Saline 0.9%;Sufentanil and PONV prophylaxis
4 Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study Not yet recruiting NCT04790305 Phase 4 Huaier Granule
5 Interstitial Brachytherapy Alone Versus External Beam Radiation Therapy After Breast Conserving Surgery for Low-risk Invasive Carcinoma and Low-risk Ductal Carcinoma in Situ (DCIS) of the Female Breast Unknown status NCT00402519 Phase 3
6 A Randomized Phase III Study to Investigate the Efficacy and Safety of Docetaxel + Capecitabine vs. Vinorelbine + Capecitabine Followed by Capecitabine Alone as 1st Therapy on Locally Advanced and Metastatic Breast Cancer Patients. Unknown status NCT01126138 Phase 3 Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine;Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine
7 A Phase III Prospective, Randomized, Double-Blind Clinical Trial of Hormone Replacement Therapy In Postmenopausal Women With A History Of Node-Negative Or Ductal Carcinoma In Situ Who Are Receiving Adjuvant Tamoxifen Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
8 Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer Completed NCT00044291 Phase 3 atamestane;toremifene;letrozole;aromatase inhibition
9 A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors Completed NCT00004205 Phase 3 letrozole;tamoxifen citrate
10 A Clinical Trial Comparing Anastrozole With Tamoxifen in Postmenopausal Patients With Ductal Carcinoma in Situ (DCIS) Undergoing Lumpectomy With Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
11 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
12 Conservative Surgery With or Without Axillary Lymphnode Removal in Treating Women With T1N0 Breast Cancer Completed NCT01508546 Phase 3
13 A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes Completed NCT02961790 Phase 3 Oxybutynin Chloride
14 A Randomized Phase II Trial Investigating the Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
15 CirCe01 Study: Evaluation of the Use of Circulating Tumour Cells to Guide Chemotherapy From the 3rd Line of Chemotherapy for Metastatic Breast Cancer Completed NCT01349842 Phase 3
16 A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto) Completed NCT01583426 Phase 3 nab-Paclitaxel;Paclitaxel
17 A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) Completed NCT02125344 Phase 3 non-pegylated liposomal doxorubicin;Carboplatin;Paclitaxel;Epirubicin;Cyclophosphamide;Pertuzumab;Trastuzumab;Ferric carboxymaltose
18 Evaluation of a New Intraoperative Gamma Camera for the Sentinel Lymph Node Procedure in Breast Cancer Completed NCT00757302 Phase 3
19 Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk and Estrogen Receptor-Positive Ductal Carcinoma in Situ of Breast: an International Open-label Randomized Non-inferiority Trial Recruiting NCT04046159 Phase 3 Low-dose tamoxifen
20 Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer Recruiting NCT03077841 Phase 2, Phase 3
21 RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction Recruiting NCT03414970 Phase 3
22 Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early Stage Human Epidermal Growth Factor Receptor-2 (HER2) Negative Breast Cancer in High-risk Women Recruiting NCT03201861 Phase 3 Paclitaxel, Cisplatin;EC to docetaxel or paclitaxel
23 Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women Recruiting NCT01905046 Phase 3 metformin hydrochloride
24 A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Recruiting NCT02879513 Phase 3 Paclitaxel;Cisplatin;Epirubicin;Cyclophosphamide;5-fluoruracil
25 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy Active, not recruiting NCT00769379 Phase 3
26 A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer Active, not recruiting NCT01272037 Phase 3 Anastrozole;Exemestane;Letrozole;Systemic Chemotherapy;Tamoxifen Citrate
27 A Randomised Phase III Study of Radiation Doses and Fractionation Schedules in Non-low Risk Ductal Carcinoma In Situ (DCIS) of the Breast Active, not recruiting NCT00470236 Phase 3
28 Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin Active, not recruiting NCT02620280 Phase 3 Carboplatin;Abraxane;MPDL3280A;Anthra
29 Phase III Trial of Tamoxifen Alone vs. Tamoxifen Plus Radiation Therapy for Good Risk Duct Carcinoma In-Situ (DCIS) of the Female Breast Active, not recruiting NCT00003857 Phase 3 tamoxifen citrate
30 A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer Active, not recruiting NCT02221999 Phase 2, Phase 3 Paclitaxel;Cisplatin;Gonadotropin-releasing hormone agonist;Letrozole
31 Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study Active, not recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
32 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
33 Randomised Trial Testing Observation (No Radiotherapy) Against Radiotherapy In Women With Low-Risk Completely Excised ER Positive Ductal Carcinoma In Situ (DCIS) Of The Breast On Adjuvant Endocrine Therapy Unknown status NCT00077168 Phase 2 anastrozole;tamoxifen citrate
34 A Phase II Randomized Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ Unknown status NCT00669747 Phase 2 Carboplatin i.d. Days 1 & 15;Carboplatin i.d. Day 1; Normal Saline i.d. Day 15;Normal Saline
35 A Phase II, Open-label, Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma Unknown status NCT01016002 Phase 2 Temoporfin
36 A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease Unknown status NCT01849250 Phase 2 Docosahexaenoic Acid
37 Multicenter (Phase II) Study of Oncoplastic Surgical Techniques for Breast Conservation in Breast Cancers Completed NCT00870415 Phase 2
38 Pre-surgical Phase IIb Trial of Transdermal 4-Hydroxytamoxifen vs. Oral Tamoxifen in Women With Ductal Carcinoma in Situ of the Breast Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
39 TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial) Completed NCT02526498 Phase 2
40 A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma Completed NCT01869764 Phase 2 omega-3 fatty acid
41 A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors Completed NCT02150525 Phase 2
42 Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast. Completed NCT03002766 Phase 2
43 Randomized Phase II Biomarker Pilot Trial of Fluvastatin Use in Women With Ductal Carcinoma in Situ (DCIS) or Stage I Breast Cancer Completed NCT00416403 Phase 2 fluvastatin sodium
44 Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS) Completed NCT01439711 Phase 2 letrozole
45 Primary Hormonal Therapy for Ductal Carcinoma in Situ: Exploration of a Novel Approach to the Clinical Management of Noninvasive Breast Cancer Completed NCT00290745 Phase 1, Phase 2 letrozole;tamoxifen citrate
46 MammoSite Radiation Therapy System (RTS) as the Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ (DCIS) Completed NCT00586326 Phase 2
47 Prospective Phase II Study of Gemcitabine Plus Platinum Salt in Combination With Bevacizumab (Avastin®) for Metastatic Collecting Duct Carcinoma Completed NCT02363751 Phase 2 Bevacizumab
48 A Phase II Prospective Pilot Study Evaluating Efficacy of Intravenous Zoledronic Acid Prophylaxis for Prevention of Aromatase Inhibitor Associated Musculoskeletal Symptoms: ZAP-AIMSS Trial Completed NCT01194440 Phase 2 letrozole;zoledronic acid
49 Sulforaphane: A Dietary Histone Deacetylase (HDAC) Inhibitor in Ductal Carcinoma in Situ (DCIS) Completed NCT00843167 Phase 2
50 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206

Search NIH Clinical Center for Breast Ductal Carcinoma

Cochrane evidence based reviews: carcinoma, ductal

Genetic Tests for Breast Ductal Carcinoma

Anatomical Context for Breast Ductal Carcinoma

MalaCards organs/tissues related to Breast Ductal Carcinoma:

40
Breast, Lymph Node, Pancreas, Liver, Skin, Endothelial, Salivary Gland

Publications for Breast Ductal Carcinoma

Articles related to Breast Ductal Carcinoma:

(show top 50) (show all 1845)
# Title Authors PMID Year
1
Mutations in the RAD54 recombination gene in primary cancers. 6
10362365 1999
2
Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression. 61 54
20043090 2010
3
E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausal women. 54 61
20349789 2010
4
[Relationship of ezrin protein expression to the carcinogenesis and prognosis of infitrating breast ductal carcinoma]. 54 61
18788632 2008
5
[Clinicopathologic significance of chromosome 17 polysomy in breast cancer]. 54 61
18681318 2008
6
P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma. 54 61
19190693 2007
7
A mutation in the 5' untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency. 61 54
17697535 2007
8
Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. 54 61
17599361 2007
9
Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. 54 61
17708365 2007
10
Identification of a basal-like subtype of breast ductal carcinoma in situ. 61 54
17234468 2007
11
An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. 54 61
17244359 2007
12
Expression of nm23, MMP-2, TIMP-2 in breast neoplasm in Zhengzhou Center Hospital, China. 54 61
17642161 2007
13
CD44 expression and axillary lymph node metastasis in infiltrating ductal carcinoma of the breast. 61 54
18376796 2006
14
E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. 54 61
16791476 2006
15
Smad4-expression is decreased in breast cancer tissues: a retrospective study. 54 61
16438724 2006
16
Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. 54 61
16080559 2005
17
Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium. 61 54
16131446 2005
18
Transient transfection of epidermal growth factor receptor gene into MCF7 breast ductal carcinoma cell line. 54 61
15584089 2005
19
PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. 61 54
15656884 2005
20
Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. 61 54
15649255 2005
21
The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. 54 61
15850004 2005
22
Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. 61 54
14736826 2004
23
Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients. 54 61
15033823 2003
24
Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. 61 54
12670886 2003
25
The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. 54 61
12713734 2003
26
Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. 61 54
12527916 2003
27
Cell proliferation, nuclear ploidy, and EGFr and HER2/neu tyrosine kinase oncoproteins in infiltrating ductal breast carcinoma. 54 61
12419588 2002
28
The angiogenic and lymphangiogenic factor vascular endothelial growth factor-D exhibits a paracrine mode of action in cancer. 61 54
12148568 2002
29
p63 expression in normal, hyperplastic and malignant breast tissues. 61 54
12185332 2002
30
p53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma. 54 61
11410327 2001
31
pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status. 61 54
11523925 2001
32
The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma. 61 54
11454996 2001
33
Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status. 61 54
11169147 2001
34
Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. 61 54
11569926 2001
35
Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. 61 54
10941333 2000
36
Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. 54 61
10754491 2000
37
Cyclin D1 overexpression in a model of human breast premalignancy: preferential stimulation of anchorage-independent but not anchorage-dependent growth is associated with increased cdk2 activity. 54 61
10752677 2000
38
Expression of glycodelin in human breast and breast cancer. 61 54
10597188 1999
39
A comparison of the pattern of cathepsin-D expression in fibroadenoma, fibrocystic disease, preinvasive and invasive ductal breast carcinoma. 54 61
10503271 1999
40
[Immunohistochemical tumor markers in infiltrating ductal breast carcinoma]. 54 61
10030093 1998
41
p53 protein expression in benign and malignant breast lesions. 54 61
9684577 1998
42
CD44 isoform expression follows two alternative splicing pathways in breast tissue. 61 54
9665479 1998
43
Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement. 61 54
9568187 1998
44
[Mammary carcinoma in a patient with hyperprolactinemia]. 54 61
9586418 1997
45
Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia. 54 61
9012463 1997
46
The intermediate filaments and prognostically oriented morphological classification in ductal breast carcinoma. 54 61
9605010 1997
47
Chromosome 1 aneusomy with 1p36 under-representation is related to histologic grade, DNA aneuploidy, high c-erb B-2 and loss of bcl-2 expression in ductal breast carcinoma. 61 54
8900371 1996
48
Reciprocal expression of Bcl-2 and p53 in breast ductal carcinoma. 61 54
8917421 1996
49
Histological grade in invasive ductal carcinoma of breast correlates with the proliferative activity evaluated by BrdU: an immunohistochemical study including correlations with p53, c-erbB-2 and estrogen receptor status. 54 61
8869993 1996
50
Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes. 61 54
8744803 1996

Variations for Breast Ductal Carcinoma

ClinVar genetic disease variations for Breast Ductal Carcinoma:

6 (show top 50) (show all 257)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RAD54L NM_003579.4(RAD54L):c.973G>A (p.Gly325Arg) SNV Pathogenic 6193 rs121908690 GRCh37: 1:46733212-46733212
GRCh38: 1:46267540-46267540
2 SLITRK6 NM_032229.3(SLITRK6):c.1915dup (p.Tyr639fs) Duplication Uncertain significance 221332 rs869312872 GRCh37: 13:86368728-86368729
GRCh38: 13:85794593-85794594
3 overlap with 6 genes GRCh37/hg19 8q22.2(chr8:100871620-101253185)x3 copy number gain Uncertain significance 221467 GRCh37: 8:100871620-101253185
GRCh38:
4 CACNA1H NM_021098.3(CACNA1H):c.1624G>A (p.Glu542Lys) SNV Uncertain significance 221328 rs761025927 GRCh37: 16:1252074-1252074
GRCh38: 16:1202074-1202074
5 overlap with 15 genes GRCh37/hg19 3p21.31(chr3:50273827-50403519)x3 copy number gain Uncertain significance 221434 GRCh37: 3:50273827-50403519
GRCh38:
6 overlap with 9 genes GRCh37/hg19 16q11.2-12.1(chr16:46615804-47345238)x1 copy number loss Uncertain significance 221520 GRCh37: 16:46615804-47345238
GRCh38:
7 ABHD12 GRCh37/hg19 20p11.21(chr20:25284225-25371245)x3 copy number gain Uncertain significance 221546 GRCh37: 20:25284225-25371245
GRCh38:
8 NIPBL GRCh37/hg19 5p13.2(chr5:37000955-37014827)x4 copy number gain Uncertain significance 221443 GRCh37: 5:37000955-37014827
GRCh38:
9 overlap with 43 genes Complex Uncertain significance 221346 GRCh37: 17:9586165-16325968
GRCh38:
10 overlap with 21 genes chr14:104643721..105932775 complex variant Complex Uncertain significance 221344 GRCh37: 14:104643721-105932775
GRCh38:
11 RP1 NM_006269.2(RP1):c.5001del (p.Arg1668fs) Deletion Uncertain significance 221333 rs869320622 GRCh37: 8:55541442-55541442
GRCh38: 8:54628882-54628882
12 overlap with 90 genes chr1:17555508-24706269 complex variant Complex Uncertain significance 221359 GRCh37: 1:17555508-24706269
GRCh38:
13 ZDBF2 NM_020923.3(ZDBF2):c.5795G>A (p.Arg1932His) SNV Uncertain significance 221299 rs763186071 GRCh37: 2:207175047-207175047
GRCh38: 2:206310323-206310323
14 overlap with 7 genes GRCh37/hg19 3q29(chr3:193333511-194338436)x3 copy number gain Uncertain significance 221436 GRCh37: 3:193333511-194338436
GRCh38:
15 NOTCH3 NM_000435.3(NOTCH3):c.5161T>A (p.Trp1721Arg) SNV Uncertain significance 221308 rs869025230 GRCh37: 19:15280935-15280935
GRCh38: 19:15170124-15170124
16 overlap with 6 genes GRCh37/hg19 22q13.33(chr22:50964500-51016275)x3 copy number gain Uncertain significance 221551 GRCh37: 22:50964500-51016275
GRCh38:
17 overlap with 5 genes GRCh37/hg19 12q21.31(chr12:80927874-81503412)x3 copy number gain Uncertain significance 221491 GRCh37: 12:80927874-81503412
GRCh38:
18 overlap with 204 genes GRCh37/hg19 16p13.3-12.3(chr16:1274615-19073133)x3 copy number gain Uncertain significance 221511 GRCh37: 16:1274615-19073133
GRCh38:
19 overlap with 176 genes GRCh37/hg19 16q12.2-22.2(chr16:55359026-70884455)x1 copy number loss Uncertain significance 221523 GRCh37: 16:55359026-70884455
GRCh38:
20 overlap with 28 genes GRCh37/hg19 20q13.33(chr20:60882468-62045494)x1 copy number loss Uncertain significance 221406 GRCh37: 20:60882468-62045494
GRCh38:
21 overlap with 58 genes GRCh38/hg38 16q12.1-12.2(chr16:48543083-53879916)x1 copy number loss Uncertain significance 221522 GRCh37: 16:48576994-53913828
GRCh38: 16:48543083-53879916
22 overlap with 33 genes chr19:56133299..57648277 complex variant Complex Uncertain significance 221354 GRCh37: 19:56133299-57648277
GRCh38:
23 overlap with 32 genes GRCh37/hg19 16p11.2(chr16:30391304-31122666)x3 copy number gain Uncertain significance 221517 GRCh37: 16:30391304-31122666
GRCh38:
24 MED13L GRCh37/hg19 12q24.21(chr12:116399137-116714901)x3 copy number gain Uncertain significance 221494 GRCh37: 12:116399137-116714901
GRCh38:
25 overlap with 317 genes Complex Uncertain significance 221334 GRCh37: 1:909238-24706269
GRCh38:
26 overlap with 30 genes GRCh37/hg19 19p13.2(chr19:8661944-10104083)x1 copy number loss Uncertain significance 221397 GRCh37: 19:8661944-10104083
GRCh38:
27 overlap with 215 genes chr1:909238-16736132 complex variant Complex Uncertain significance 221357 GRCh37: 1:909238-16736132
GRCh38:
28 overlap with 25 genes Complex Uncertain significance 221349 GRCh37: 19:9001833-10085054
GRCh38:
29 overlap with 6 genes GRCh37/hg19 1p13.2(chr1:113134186-113265713)x3 copy number gain Uncertain significance 221415 GRCh37: 1:113134186-113265713
GRCh38:
30 overlap with 4 genes GRCh37/hg19 16p11.2(chr16:31123271-31153163)x4 copy number gain Uncertain significance 221518 GRCh37: 16:31123271-31153163
GRCh38:
31 overlap with 7 genes GRCh38/hg38 16q12.1(chr16:47497444-48230506)x1 copy number loss Uncertain significance 221521 GRCh37: 16:47531355-48264417
GRCh38: 16:47497444-48230506
32 overlap with 25 genes GRCh38/hg38 17p13.1-12(chr17:9701182-11983353)x1 copy number loss Uncertain significance 221395 GRCh37: 17:9604499-11886670
GRCh38: 17:9701182-11983353
33 overlap with 34 genes GRCh37/hg19 19q13.42(chr19:54710237-55648526)x1 copy number loss Uncertain significance 221404 GRCh37: 19:54710237-55648526
GRCh38:
34 overlap with 5 genes chr19:55143156-55294969 complex variant Complex Uncertain significance 221370 GRCh37: 19:55143156-55294969
GRCh38:
35 overlap with 51 genes GRCh37/hg19 16p13.3(chr16:97494-1257060)x3 copy number gain Uncertain significance 221390 GRCh37: 16:97494-1257060
GRCh38:
36 overlap with 4 genes GRCh38/hg38 9q34.3(chr9:135665886-135775364)x1 copy number loss Uncertain significance 221387 GRCh37: 9:138557731-138667209
GRCh38: 9:135665886-135775364
37 overlap with 30 genes chr19:54754752-55624113 complex variant Complex Uncertain significance 221353 GRCh37: 19:54754752-55624113
GRCh38:
38 overlap with 18 genes GRCh37/hg19 16p13.3(chr16:324072-705832)x3 copy number gain Uncertain significance 221508 GRCh37: 16:324072-705832
GRCh38:
39 overlap with 28 genes GRCh37/hg19 19q13.42-13.43(chr19:56200298-57654005)x1 copy number loss Uncertain significance 221405 GRCh37: 19:56200298-57654005
GRCh38:
40 overlap with 8 genes GRCh37/hg19 6p22.2-22.1(chr6:26545571-27115102)x3 copy number gain Uncertain significance 221452 GRCh37: 6:26545571-27115102
GRCh38:
41 overlap with 81 genes chr12:10074776-18800953 complex variant Complex Uncertain significance 221369 GRCh37: 12:10074776-18800953
GRCh38:
42 overlap with 370 genes GRCh37/hg19 16q11.2-24.3(chr16:46615804-90142285)x1 copy number loss Uncertain significance 221392 GRCh37: 16:46615804-90142285
GRCh38:
43 overlap with 5 genes GRCh37/hg19 1q21.3(chr1:150531540-150679158)x3 copy number gain Uncertain significance 221418 GRCh37: 1:150531540-150679158
GRCh38:
44 overlap with 24 genes chr19:44501518-45322744 complex variant Complex Uncertain significance 221352 GRCh37: 19:44501518-45322744
GRCh38:
45 overlap with 142 genes GRCh37/hg19 16q22.2-24.3(chr16:72107834-90142285)x1 copy number loss Uncertain significance 221527 GRCh37: 16:72107834-90142285
GRCh38:
46 LRP6 GRCh38/hg38 12p13.2(chr12:12198797-12200966)x1 copy number loss Uncertain significance 221487 GRCh37: 12:9906131-19671632
GRCh38: 12:12198797-12200966
47 CEP43 GRCh37/hg19 6q27(chr6:167412952-167447412)x3 copy number gain Uncertain significance 221459 GRCh37: 6:167412952-167447412
GRCh38:
48 PML NM_033238.3(PML):c.2264G>C (p.Arg755Pro) SNV Uncertain significance 221319 rs780746013 GRCh37: 15:74336964-74336964
GRCh38: 15:74044623-74044623
49 overlap with 326 genes Complex Uncertain significance 221345 GRCh37: 16:56368689-90141355
GRCh38:
50 overlap with 386 genes GRCh37/hg19 16p13.3-11.2(chr16:1279324-31926800)x3 copy number gain Uncertain significance 221391 GRCh37: 16:1279324-31926800
GRCh38:

Cosmic variations for Breast Ductal Carcinoma:

9 (show top 50) (show all 14495)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM103978702 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3423G>A p.K1141= 10:73797261-73797261 9
2 COSM143704807 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3408G>A p.K1136= 10:73797261-73797261 9
3 COSM143340021 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3423G>A p.K1141= 10:73797261-73797261 9
4 COSM143155659 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3408G>A p.K1136= 10:73797261-73797261 9
5 COSM141577245 ZSWIM8 breast,NS,carcinoma,ductal carcinoma c.3309G>A p.K1103= 10:73797261-73797261 9
6 COSM88263804 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1084G>A p.E362K 23:15822877-15822877 9
7 COSM88263027 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1406C>T p.S469L 23:15823199-15823199 9
8 COSM88262392 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.1312G>T p.G438C 23:15823105-15823105 9
9 COSM88264460 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.267G>C p.K89N 23:15803751-15803751 9
10 COSM88263630 ZRSR2 breast,NS,carcinoma,ductal carcinoma c.989A>G p.H330R 23:15822782-15822782 9
11 COSM90724063 ZNHIT2 breast,NS,carcinoma,ductal carcinoma c.175G>C p.A59P 11:65117479-65117479 9
12 COSM96875678 ZNF830 breast,NS,carcinoma,ductal carcinoma c.136A>G p.N46D 17:34961702-34961702 9
13 COSM101741828 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 9
14 COSM133260197 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 9
15 COSM133259918 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 9
16 COSM101741790 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 9
17 COSM131594768 ZNF668 breast,NS,carcinoma,ductal carcinoma c.925G>A p.G309S 16:31062072-31062072 9
18 COSM87497387 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 9
19 COSM87497658 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 9
20 COSM132355503 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 9
21 COSM132355522 ZNF668 breast,NS,carcinoma,ductal carcinoma c.856G>A p.G286S 16:31062072-31062072 9
22 COSM131594485 ZNF668 breast,NS,carcinoma,ductal carcinoma c.265G>A p.A89T 16:31064264-31064264 9
23 COSM131594753 ZNF668 breast,NS,carcinoma,ductal carcinoma c.1061C>G p.T354R 16:31061936-31061936 9
24 COSM132355306 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 9
25 COSM108404990 ZNF668 breast,NS,carcinoma,ductal carcinoma c.265G>A p.A89T 16:31064264-31064264 9
26 COSM101741584 ZNF668 breast,NS,carcinoma,ductal carcinoma c.196G>A p.A66T 16:31064264-31064264 9
27 COSM133260145 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 9
28 COSM108405155 ZNF668 breast,NS,carcinoma,ductal carcinoma c.1061C>G p.T354R 16:31061936-31061936 9
29 COSM87497622 ZNF668 breast,NS,carcinoma,ductal carcinoma c.992C>G p.T331R 16:31061936-31061936 9
30 COSM108405172 ZNF668 breast,NS,carcinoma,ductal carcinoma c.925G>A p.G309S 16:31062072-31062072 9
31 COSM87511923 ZNF646 breast,NS,carcinoma,ductal carcinoma c.4010A>T p.N1337I 16:31080334-31080334 9
32 COSM101729269 ZNF646 breast,NS,carcinoma,ductal carcinoma c.4010A>T p.N1337I 16:31080334-31080334 9
33 COSM92054903 ZNF644 breast,NS,carcinoma,ductal carcinoma c.23-23043G>C p.? 1:90941197-90941197 9
34 COSM95319541 ZNF644 breast,NS,carcinoma,ductal carcinoma c.157G>C p.E53Q 1:90941197-90941197 9
35 COSM94049964 ZNF644 breast,NS,carcinoma,ductal carcinoma c.23-23043G>C p.? 1:90941197-90941197 9
36 COSM91884936 ZNF644 breast,NS,carcinoma,ductal carcinoma c.157G>C p.E53Q 1:90941197-90941197 9
37 COSM139305666 ZNF569 breast,NS,carcinoma,ductal carcinoma c.157C>G p.Q53E 19:37426309-37426309 9
38 COSM91675445 ZNF569 breast,NS,carcinoma,ductal carcinoma c.85C>G p.Q29E 19:37426309-37426309 9
39 COSM100881762 ZNF569 breast,NS,carcinoma,ductal carcinoma c.85C>G p.Q29E 19:37426309-37426309 9
40 COSM100886533 ZNF569 breast,NS,carcinoma,ductal carcinoma c.-239-11890C>G p.? 19:37426309-37426309 9
41 COSM139323876 ZNF569 breast,NS,carcinoma,ductal carcinoma c.16-11890C>G p.? 19:37426309-37426309 9
42 COSM90464551 ZNF548 breast,NS,carcinoma,ductal carcinoma c.70G>T p.D24Y 19:57397066-57397066 9
43 COSM139958759 ZNF548 breast,NS,carcinoma,ductal carcinoma c.70G>T p.D24Y 19:57397066-57397066 9
44 COSM93683315 ZNF548 breast,NS,carcinoma,ductal carcinoma c.34G>T p.D12Y 19:57397066-57397066 9
45 COSM140877756 ZNF548 breast,NS,carcinoma,ductal carcinoma c.70G>T p.D24Y 19:57397066-57397066 9
46 COSM141497466 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 9
47 COSM90396499 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 9
48 COSM141373096 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 9
49 COSM139185737 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 9
50 COSM139904572 ZNF532 breast,NS,carcinoma,ductal carcinoma c.2465C>T p.S822L 18:58934551-58934551 9

Copy number variations for Breast Ductal Carcinoma from CNVD:

7 (show all 33)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 50888 11 119630000 120260000 Deletion Ductal carcinoma
2 57116 11 63100000 76700000 Amplification CCND1 Ductal carcinoma
3 58629 11 68930000 70160000 Gain Ductal carcinoma
4 58724 11 69230000 69780000 Gain Ductal carcinoma
5 59882 11 78860000 79330000 Deletion Ductal carcinoma
6 60225 11 84000000 88080000 Deletion Ductal carcinoma
7 60766 11 91240000 95940000 Deletion Ductal carcinoma
8 66468 12 2966849 2986303 Copy number FOXM1 Ductal carcinoma
9 98103 16 15360000 17700000 Gain Ductal carcinoma
10 99317 16 25030000 27880000 Gain Ductal carcinoma
11 101507 16 40000 40090000 Gain Ductal carcinoma
12 107663 17 16530000 18020000 Deletion Ductal carcinoma
13 109740 17 28800000 35400000 Amplification ERBB2 Ductal carcinoma
14 116392 17 6500000 10700000 Copy number TP53 Ductal carcinoma
15 117043 17 70920000 72340000 Gain Ductal carcinoma
16 126771 19 20810000 63790000 Gain Ductal carcinoma
17 127047 19 23780000 51950000 Gain Ductal carcinoma
18 128079 19 39420000 40350000 Gain Ductal carcinoma
19 131070 19 52760000 63790000 Gain Ductal carcinoma
20 153161 20 34860000 62370000 Gain Ductal carcinoma
21 153748 20 41100000 62435964 Amplification BMP7 Ductal carcinoma
22 166731 3 107740000 107880000 Deletion Ductal carcinoma
23 166830 3 108620000 110660000 Deletion Ductal carcinoma
24 167069 3 112930000 115910000 Deletion Ductal carcinoma
25 179845 3 99790000 104540000 Deletion Ductal carcinoma
26 196641 5 170120000 170210000 Gain Ductal carcinoma
27 196700 5 170690000 172750000 Gain Ductal carcinoma
28 215548 6 77380000 82650000 Deletion Ductal carcinoma
29 231989 8 110000 5150000 Deletion Ductal carcinoma
30 233354 8 124380000 129070000 Gain Ductal carcinoma
31 234986 8 140450000 141700000 Gain Ductal carcinoma
32 238072 8 29700000 38500000 Amplification FGFR1 Ductal carcinoma
33 239766 8 41480000 42480000 Gain Ductal carcinoma

Expression for Breast Ductal Carcinoma

Search GEO for disease gene expression data for Breast Ductal Carcinoma.

Pathways for Breast Ductal Carcinoma

Pathways related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 VEGFD TP53 PIP ESR1 ERBB2 EGFR
2
Show member pathways
13.28 VEGFD ESR1 ERBB2 EGFR CTNNB1 CDH3
3
Show member pathways
12.9 VEGFD TP53 ERBB2 EGFR CTNNB1 CCND1
4
Show member pathways
12.87 TP53 ERBB2 EGFR CTNNB1 CDH1 CCND1
5
Show member pathways
12.72 TP53 ESR1 ERBB2 CTNNB1 CDH1
6 12.58 VEGFD TP53 ESR1 ERBB2 EGFR CTNNB1
7
Show member pathways
12.57 VEGFD TFF1 PGR ESR1 EGFR CTSD
8
Show member pathways
12.55 TP53 ESR1 ERBB2 EGFR CDH1 CCND1
9 12.54 TP53 ERBB2 EGFR CCND1 BRCA1
10 12.5 TP53 RAD54L MKI67 CCND1 BRCA1
11
Show member pathways
12.44 TP53 ERBB2 EGFR CTNNB1
12
Show member pathways
12.41 VEGFD ERBB2 EGFR CTNNB1 CDH1
13 12.39 TP53 CTNNB1 CDH3 CDH1 CCND1
14
Show member pathways
12.34 ERBB2 EGFR CTNNB1 CDH1
15
Show member pathways
12.28 TP53 PGR ESR1 ERBB2 EGFR CTNNB1
16
Show member pathways
12.26 TFF1 ESR1 ERBB2 EGFR CCND1
17
Show member pathways
12.23 PGR ESR1 CCND1 BRCA1
18
Show member pathways
12.23 TP53 ERBB2 EGFR CTNNB1 CCND1
19 12.11 TP53 ESR1 ERBB2 EGFR CTNNB1 CCND1
20 12.05 TP53 EGFR CTNNB1 CDH1 CCND1
21 12.01 TFF1 CTNNB1 CDH3 CDH1
22 12 TP53 ESR1 CTNNB1 CCND1
23 11.94 TP53 ERBB2 CTNNB1 CCND1
24 11.91 TP53 EGFR CTNNB1 CCND1
25
Show member pathways
11.89 PGR ESR1 ERBB2 EGFR
26 11.81 EGFR CTNNB1 CCND1 BRCA1
27 11.79 CTNNB1 CDH1 CCND1
28 11.75 MKI67 KRT8 CTNNB1
29 11.75 TP53 ERBB2 BRCA1
30
Show member pathways
11.73 ESR1 EGFR CCND1
31 11.72 TP53 ERBB2 EGFR
32 11.71 ERBB2 EGFR CTNNB1
33 11.69 ESR1 EGFR CCND1
34 11.69 TP53 ERBB2 BRCA1
35 11.65 ERBB2 CCND1 BRCA1
36 11.62 CTNNB1 CCND1 BRCA1
37 11.61 ERBB2 EGFR CTNNB1 CDH1
38 11.56 TP53 EGFR CCND1
39 11.56 TP53 CCND1 BRCA1
40
Show member pathways
11.51 TFF1 ESR1 BRCA1
41 11.49 TP53 CCND1 BRCA1
42 11.48 NME1 CTNNB1 CDH1
43 11.46 TP53 ESR1 CTSD
44 11.43 EGFR CTNNB1 CDH1
45 11.43 CTNNB1 CDH3 CDH1
46 11.42 TP53 ERBB2 EGFR CDH1 CCND1
47 11.41 TP53 RAD54L ESR1 EGFR CTNNB1 CDH1
48 11.35 TP53 KRT8 ESR1
49 11.32 TP53 EGFR CTNNB1
50 11.29 TP53 CCND1 BRCA1

GO Terms for Breast Ductal Carcinoma

Cellular components related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.1 ZFAS1 TP53 RAD54L PIP PGR NME1
2 protein-containing complex GO:0032991 9.43 TP53 RAD54L ESR1 EGFR CTNNB1 BRCA1
3 flotillin complex GO:0016600 9.16 CTNNB1 CDH1
4 catenin complex GO:0016342 8.8 CTNNB1 CDH3 CDH1

Biological processes related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.99 TP53 ESR1 EGFR CTNNB1 CDH1 BRCA1
2 positive regulation of protein phosphorylation GO:0001934 9.86 VEGFD ERBB2 EGFR CCND1
3 negative regulation of gene expression GO:0010629 9.83 TP53 PGR NME1 ESR1 CTNNB1
4 positive regulation of gene expression GO:0010628 9.8 TP53 PIP ERBB2 CTNNB1 CDH3 BRCA1
5 cell-cell adhesion GO:0098609 9.78 EGFR CTNNB1 CDH3 CDH1
6 cellular response to drug GO:0035690 9.77 TP53 NME1 EGFR
7 cellular response to growth factor stimulus GO:0071363 9.77 ERBB2 EGFR CTNNB1
8 double-strand break repair GO:0006302 9.74 TP53 RAD54L BRCA1
9 positive regulation of epithelial cell proliferation GO:0050679 9.72 NME1 ERBB2 EGFR
10 response to estrogen GO:0043627 9.71 ESR1 CCND1 BRCA1
11 regulation of apoptotic process GO:0042981 9.65 TP53 NME1 ESR1 CTNNB1 BRCA1
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.63 TP53 EGFR
13 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.63 TP53 ESR1
14 adherens junction organization GO:0034332 9.63 CTNNB1 CDH3 CDH1
15 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.62 TP53 ESR1
16 intracellular steroid hormone receptor signaling pathway GO:0030518 9.62 PGR ESR1
17 positive regulation of execution phase of apoptosis GO:1900119 9.61 TP53 FAP
18 mitotic G1 DNA damage checkpoint GO:0031571 9.61 TP53 CCND1
19 entry of bacterium into host cell GO:0035635 9.58 CTNNB1 CDH1
20 DNA strand renaturation GO:0000733 9.58 TP53 RAD54L
21 positive regulation of cell cycle arrest GO:0071158 9.54 TP53 FAP BRCA1
22 hair cycle process GO:0022405 9.52 CTNNB1 CDH3
23 negative regulation of ERBB signaling pathway GO:1901185 9.49 ERBB2 EGFR
24 response to estradiol GO:0032355 9.46 ESR1 EGFR CTNNB1 CCND1
25 response to UV-A GO:0070141 9.4 EGFR CCND1
26 response to drug GO:0042493 9.17 TP53 RAD54L NME1 CTNNB1 CDH3 CDH1
27 cellular response to indole-3-methanol GO:0071681 9.13 CTNNB1 CDH1 BRCA1

Molecular functions related to Breast Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 TP53 ESR1 EGFR CTNNB1 CCND1
2 identical protein binding GO:0042802 9.7 VEGFD TP53 PIP PGR NME1 FAP
3 beta-catenin binding GO:0008013 9.58 ESR1 CTNNB1 CDH1
4 ATPase binding GO:0051117 9.54 PGR ESR1 EGFR
5 protein phosphatase binding GO:0019903 9.46 TP53 ERBB2 EGFR CTNNB1
6 nitric-oxide synthase regulator activity GO:0030235 9.26 ESR1 EGFR
7 enzyme binding GO:0019899 9.23 TP53 PGR NME1 ESR1 EGFR CTNNB1

Sources for Breast Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....